Point72 Asia Singapore Pte. Ltd. Has $61,000 Stock Position in OPKO Health, Inc. (NASDAQ:OPK)

Point72 Asia Singapore Pte. Ltd. reduced its holdings in OPKO Health, Inc. (NASDAQ:OPK) by 55.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 41,589 shares of the biotechnology company’s stock after selling 51,110 shares during the quarter. Point72 Asia Singapore Pte. Ltd.’s holdings in OPKO Health were worth $61,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Millennium Management LLC boosted its holdings in OPKO Health by 85.3% in the fourth quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company’s stock worth $6,745,000 after acquiring an additional 2,112,382 shares in the last quarter. Lazard Asset Management LLC raised its position in shares of OPKO Health by 143.6% during the fourth quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company’s stock worth $3,746,000 after purchasing an additional 1,502,342 shares during the period. Altshuler Shaham Ltd bought a new position in shares of OPKO Health in the 4th quarter worth $2,082,000. Norges Bank acquired a new stake in OPKO Health in the 4th quarter valued at $1,657,000. Finally, Marshall Wace LLP increased its stake in OPKO Health by 856.5% during the 4th quarter. Marshall Wace LLP now owns 921,487 shares of the biotechnology company’s stock valued at $1,355,000 after purchasing an additional 825,143 shares in the last quarter. 64.63% of the stock is owned by institutional investors and hedge funds.

OPKO Health Stock Performance

Shares of OPK stock opened at $1.33 on Monday. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The firm has a 50-day moving average of $1.51 and a 200-day moving average of $1.56. OPKO Health, Inc. has a one year low of $1.19 and a one year high of $2.04. The company has a market cap of $1.05 billion, a P/E ratio of -7.00 and a beta of 1.42.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.03). OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The firm had revenue of $149.90 million during the quarter, compared to analysts’ expectations of $163.13 million. During the same quarter last year, the business posted ($0.12) EPS. The company’s quarterly revenue was down 13.7% on a year-over-year basis. Equities research analysts forecast that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

Insider Activity at OPKO Health

In related news, CEO Phillip Md Et Al Frost bought 200,000 shares of OPKO Health stock in a transaction dated Monday, March 17th. The stock was purchased at an average cost of $1.74 per share, with a total value of $348,000.00. Following the transaction, the chief executive officer now directly owns 213,501,448 shares of the company’s stock, valued at approximately $371,492,519.52. The trade was a 0.09% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders acquired 767,434 shares of company stock valued at $1,238,312. 49.69% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts have weighed in on OPK shares. JPMorgan Chase & Co. initiated coverage on shares of OPKO Health in a research note on Friday, April 25th. They issued a “neutral” rating on the stock. Barrington Research reaffirmed an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a research report on Thursday, May 1st. StockNews.com downgraded OPKO Health from a “hold” rating to a “sell” rating in a research note on Monday, May 5th. Finally, HC Wainwright reissued a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a research note on Monday, April 7th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, OPKO Health currently has a consensus rating of “Hold” and a consensus target price of $2.75.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.